S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
US Dollar Replaced By "Biden Bucks"? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
US Dollar Replaced By "Biden Bucks"? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
US Dollar Replaced By "Biden Bucks"? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
US Dollar Replaced By "Biden Bucks"? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
NASDAQ:QURE

uniQure - QURE Stock Forecast, Price & News

$19.22
+0.53 (+2.84%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.39
$19.23
50-Day Range
$13.38
$25.54
52-Week Range
$12.52
$38.80
Volume
360,840 shs
Average Volume
814,001 shs
Market Capitalization
$898.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.38

uniQure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
151.7% Upside
$48.38 Price Target
Short Interest
Bearish
8.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of uniQure in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$947,359 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.61) to ($1.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

634th out of 1,119 stocks

Pharmaceutical Preparations Industry

308th out of 549 stocks

QURE stock logo

About uniQure (NASDAQ:QURE) Stock

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Analysts Set New Price Targets

A number of research firms have weighed in on QURE. TheStreet cut shares of uniQure from a "c-" rating to a "d" rating in a research note on Tuesday, August 9th. Wells Fargo & Company decreased their target price on shares of uniQure from $34.00 to $24.00 and set an "equal weight" rating on the stock in a research note on Tuesday, August 9th. StockNews.com cut shares of uniQure from a "hold" rating to a "sell" rating in a research note on Wednesday, August 10th. Chardan Capital reduced their price objective on shares of uniQure from $65.00 to $60.00 and set a "buy" rating on the stock in a research note on Tuesday, August 9th. Finally, Stifel Nicolaus reduced their price objective on shares of uniQure from $66.00 to $37.00 in a research note on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average price target of $48.38.

uniQure Trading Up 0.2 %

QURE Stock traded up $0.03 during midday trading on Thursday, hitting $18.72. The stock had a trading volume of 2,941 shares, compared to its average volume of 801,664. The firm has a market cap of $874.79 million, a P/E ratio of -7.63 and a beta of 1.01. The company has a current ratio of 10.84, a quick ratio of 10.78 and a debt-to-equity ratio of 0.21. uniQure has a 1-year low of $12.52 and a 1-year high of $38.80. The business has a fifty day moving average price of $20.39 and a two-hundred day moving average price of $17.74.

Insider Activity at uniQure

In related news, VP Alexander Edward Kuta III sold 5,643 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $25.00, for a total value of $141,075.00. Following the transaction, the vice president now owns 95,196 shares in the company, valued at $2,379,900. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, VP Alexander Edward Kuta III sold 5,643 shares of the company's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $25.00, for a total transaction of $141,075.00. Following the transaction, the vice president now owns 95,196 shares in the company, valued at $2,379,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Pierre Caloz sold 7,575 shares of the company's stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $13.21, for a total transaction of $100,065.75. Following the transaction, the chief operating officer now owns 64,511 shares in the company, valued at approximately $852,190.31. The disclosure for this sale can be found here. Insiders have sold a total of 42,263 shares of company stock worth $947,359 over the last quarter. Company insiders own 3.10% of the company's stock.

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Stock News Headlines

uniQure (NASDAQ:QURE) Lowered to "D" at TheStreet
Analysts Set uniQure (NASDAQ:QURE) PT at $49.43
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Company Calendar

Last Earnings
10/24/2021
Today
8/19/2022
Next Earnings (Estimated)
10/24/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
463
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.38
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+151.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$329.59 million
Net Margins
-184.06%
Pretax Margin
-185.98%

Debt

Sales & Book Value

Annual Sales
$524 million
Cash Flow
$7.51 per share
Book Value
$10.41 per share

Miscellaneous

Free Float
45,280,000
Market Cap
$898.15 million
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Matthew Craig KapustaMr. Matthew Craig Kapusta (Age 50)
    CEO & Exec. Director
    Comp: $969.95k
  • Mr. Christian  KlemtMr. Christian Klemt (Age 49)
    CFO, Principal Financial Officer & GM of Amsterdam Site
    Comp: $505.02k
  • Mr. Pierre Caloz
    Chief Operating Officer
  • Dr. Alexander E. Kuta Ph.D. (Age 62)
    Exec. VP of Quality & Regulatory Affairs
    Comp: $649.26k
  • Dr. Ricardo  Dolmetsch Ph.D.Dr. Ricardo Dolmetsch Ph.D. (Age 53)
    Pres of R&D
    Comp: $795.35k
  • Prof. Hugo Katus
    Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Mr. David Cerveny (Age 55)
    Chief Legal Officer, Gen. Counsel & Sec.
  • Dr. Tamara Tugal Ph.D.
    MBA, Bus. Devel. Director
  • Ms. Erin Boyer
    Chief People & Culture Office
  • Ms. Maria E. Cantor (Age 54)
    Chief Corp. Affairs Officer













QURE Stock - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price forecast for 2022?

8 Wall Street analysts have issued 12 month price targets for uniQure's shares. Their QURE share price forecasts range from $24.00 to $66.00. On average, they predict the company's stock price to reach $48.38 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2022?

uniQure's stock was trading at $20.74 at the beginning of 2022. Since then, QURE shares have decreased by 7.3% and is now trading at $19.22.
View the best growth stocks for 2022 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 24th 2022.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its quarterly earnings data on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.26. The biotechnology company had revenue of $2 million for the quarter, compared to analysts' expectations of $2.13 million. uniQure had a negative net margin of 184.06% and a negative trailing twelve-month return on equity of 20.56%. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the company posted ($1.21) EPS.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (8.17%), FMR LLC (5.96%), State Street Corp (5.06%), JPMorgan Chase & Co. (1.72%), Price T Rowe Associates Inc. MD (1.02%) and Privium Fund Management B.V. (0.99%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Leonard E Post, Matthew C Kapusta, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $19.22.

How much money does uniQure make?

uniQure (NASDAQ:QURE) has a market capitalization of $898.13 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does uniQure have?

The company employs 463 workers across the globe.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.

This page (NASDAQ:QURE) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.